II
FPRX

Inspire Investing’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Inspire Investing’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-86
Closed – – 782
2020
Q1 		$0 Buy
+86
New +$365 ﹤0.01% 823
2018
Q1 		– Sell
-2,868
Closed -$63K – 819
2017
Q4 		$63K Buy
+2,868
New +$92.2K 0.05% 258

Other funds holding FPRX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Inspire Investing's FPRX Position: Q2 2020 in Review

Inspire Investing sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2020, closing a stake of 86 shares.

Inspire Investing first reported a position in FPRX in Q4 2017 and held it in 2 quarters. The position peaked at $63K in Q4 2017. 98 funds tracked by Wall St. Rank hold FPRX as of Q2 2020.

  • Inspire Investing reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2020 after selling out during the quarter.
  • Inspire Investing sold 86 Five Prime Therapeutics, Inc. shares in Q2 2020.
  • Inspire Investing first reported a position in Five Prime Therapeutics, Inc. in Q4 2017 and held it in 2 quarters.
  • Inspire Investing's Five Prime Therapeutics, Inc. position peaked at $63K in Q4 2017.
  • 98 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2020.

Based on Inspire Investing's 13F filing for Q2 2020, filed 12 Aug 2020.